Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesFDA approves Reclast to prevent osteoporosis in postmenopausal women with convenient less frequent dosing
Novartis, 06/02/09
Reclast Injection has been approved by the US Food and Drug Administration as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast, or Aclasta as it is known outside the US, is already approved in more than 80 countries including the US and EU as a once-yearly infusion for the treatment of postmenopausal osteoporosis.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
Journal of Pharmacy and Pharmacology, 12/15/09
Novel TNF antagonists for the treatment of rheumatoid arthritis
Expert Opinion on Investigational Drugs, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor